author-photo

I. Haugen

Algeta

5

Papers

19

Citations

Citation Trend

Filter By

Papers (5) Sort By

Journal Conference Others

Impact of Prior Docetaxel, Extent of Disease (EOD), and Prior Bisphosphonates (Bp) on Hematologic (Heme) Safety of Radium-223 Dichloride (Ra-223) From ALSYMPCA

2014 International Journal of Radiation Oncology Biology Physics
Show All
- Source
- Cite
- Save
Citations (5)
P078 Further characterization of the effects on sequential treatment of docetaxel before or after radium-223 dichloride therapy in Castration-Resistant Prostate Cancer (CRPC) patients with symptomatic bone metastases included in the phase 3 ALSYMPCA trial

2014 European Urology Supplements
Show All
- Source
- Cite
- Save
Citations (0)
7008 POSTER DISCUSSION Twenty-four-month Safety Data From Phase II Studies of Radium-223 Chloride, a First-in-class Alpha-pharmaceutical With a Highly Favorable Safety Profile for Patients With Castration-resistant Prostate Cancer (CRPC) and Bone Metastases

2011 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (1)
Radium-223 chloride, a first-in-class alpha-pharmaceutical with a benign safety profile for patients with castration-resistant prostate cancer (CRPC) and bone metastases: Combined analysis of phase I and II clinical trials.

2010 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (10)
Alpharadin, a novel, highly targeted alpha pharmaceutical with a good safety profile for patients with CRPC and bone metastases: Combined safety analyses of phase I and II clinical trials

2009
Show All
- Source
- Cite
- Save
Citations (3)